{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-093512","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2026-08-25T20:05:29+00:00","discovered_at":"2026-08-25T20:06:02.722562+00:00","generated_at":"2026-08-25T20:06:28.646487+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vyome Q2 2026 net loss $0.7M; advances VT-1953 FDA plan, in-licenses JAK inhibitors","bullets":["Net loss of $720K ($0.10/share) for Q2 2026; cash $7.9M vs $5.0M at Dec 31, 2025.","Received FDA written response on VT-1953 pivotal study strategy; plans Type C meeting.","In-licensed two selective JAK inhibitor assets from Impetis Biosciences for autoimmune conditions.","Granted Chinese patent for VB-1953 topical gel formulation and therapeutic acne claims.","Phase 2 VT-1953 data showed significant malodor/pain reductions with no treatment-emergent AEs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-093512","json":"https://secwatch.observer/filing/0001213900-26-093512.json","markdown":"https://secwatch.observer/filing/0001213900-26-093512.md","text":"https://secwatch.observer/filing/0001213900-26-093512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000121390026093512/0001213900-26-093512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000121390026093512/ea0303228-8k_vyome.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-25T20:06:28.646487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}